Skip to content
Relatix Health

Relatix Health

Radically different

  • Participate
    • Start here
  • Services
    • Tests to participate in
  • Resources
  • About
    • Our Vision – A radically different future
    • Our mission – personalised lifelong support
    • News
    • FAQ
    • Contact
    • Trust and Privacy
    • Support us
  • Log in / Sign up
Posted on June 18, 2026 by admin
<![CDATA[Alkermes’ phase 2 Vibrance-2 shows alixorexton significantly boosts wakefulness and reduces daytime sleepiness in narcolepsy type 2, with benefits sustained.]]>
CategoriesUncategorized TagsClinical trial, Sleep and arousal regulation, Sleep-related parasomnias

Post navigation

Previous PostPrevious Videos on Bilibili, TikTok, and Xiaohongshu as Sources of Medical Information on Adenoid Hypertrophy: Cross-Sectional Content Analysis
Next PostNext New hope in treating Huntington’s disease and a report card on RFK Jr.’s promises
Relatix Health

Relatix Health helps people understand their minds, explore relevant support and take part in research on their own terms. We connect lived experience with responsible research while protecting privacy, dignity and choice.

For researchers, clinicians and organisations, visit our sister site, Relatix Bio.

Take part

Start here Participate Tests to participate in Log in or sign up

Find support

Resources Services FAQ I need help now

Our commitments

Our Vision Our Mission Trust and Privacy

About

About us News Support us Contact

© 2026 Relatix Health. All rights reserved.